Arohi Asset Management PTE Ltd. Has $16.21 Million Position in Illumina, Inc. (NASDAQ:ILMN)

Arohi Asset Management PTE Ltd. boosted its position in Illumina, Inc. (NASDAQ:ILMN) by 91.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 121,270 shares of the life sciences company’s stock after buying an additional 58,070 shares during the quarter. Illumina makes up about 4.4% of Arohi Asset Management PTE Ltd.’s holdings, making the stock its 4th largest position. Arohi Asset Management PTE Ltd.’s holdings in Illumina were worth $16,205,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in the company. Versant Capital Management Inc raised its stake in Illumina by 153.7% in the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock valued at $32,000 after acquiring an additional 146 shares during the period. Golden State Wealth Management LLC purchased a new position in shares of Illumina in the fourth quarter worth about $32,000. Assetmark Inc. raised its position in shares of Illumina by 954.8% in the fourth quarter. Assetmark Inc. now owns 327 shares of the life sciences company’s stock valued at $44,000 after purchasing an additional 296 shares during the period. Bank Julius Baer & Co. Ltd Zurich bought a new stake in shares of Illumina in the fourth quarter valued at approximately $45,000. Finally, Lee Danner & Bass Inc. bought a new position in Illumina in the 4th quarter worth approximately $48,000. 89.42% of the stock is currently owned by institutional investors.

Illumina Price Performance

Shares of Illumina stock opened at $77.88 on Friday. The firm has a market capitalization of $12.33 billion, a PE ratio of -10.14, a price-to-earnings-growth ratio of 1.60 and a beta of 1.38. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63. Illumina, Inc. has a 12 month low of $68.70 and a 12 month high of $156.66. The business’s 50-day moving average price is $80.07 and its 200-day moving average price is $115.86.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. Sell-side analysts forecast that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on ILMN shares. Piper Sandler boosted their target price on shares of Illumina from $185.00 to $190.00 and gave the company an “overweight” rating in a report on Monday, February 10th. Hsbc Global Res lowered Illumina from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 28th. Barclays cut their target price on Illumina from $100.00 to $77.00 and set an “underweight” rating for the company in a research note on Thursday, April 10th. HSBC cut Illumina from a “buy” rating to a “hold” rating and set a $100.00 price target on the stock. in a research report on Friday, February 28th. Finally, Guggenheim cut their price objective on shares of Illumina from $170.00 to $150.00 and set a “buy” rating for the company in a research report on Friday, February 7th. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $137.55.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.